Myotonia congenita and myotonic dystrophy: Surveillance and management

Current Treatment Options in Neurology

Volumn 12, Issue 1, 2010, Pages 16-28

  Conravey, Allison ^a   Santana Gould, Lenay ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CISPLATIN; CLARITHROMYCIN; CLOMIPRAMINE; CLOZAPINE; DANAZOL; DILTIAZEM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISONIAZID; LITHIUM; LORATADINE; METOPROLOL; MEXILETINE; MODAFINIL; NEFAZODONE; NICOTINAMIDE; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TERFENADINE; THEOPHYLLINE; TOCAINIDE; UNINDEXED DRUG; VERAPAMIL;

AGRANULOCYTOSIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ASSISTIVE TECHNOLOGY DEVICE; ATAXIA; BACKACHE; BLURRED VISION; BONE MARROW DEPRESSION; BREATHING EXERCISE; CARDIOVASCULAR DISEASE; CATARACT; COARSE FACE; COGNITIVE DEFECT; CONSTIPATION; COORDINATION; DAYTIME SOMNOLENCE; DIABETES INSIPIDUS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CLASSIFICATION; DISEASE SURVEILLANCE; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; ENDOCRINE DISEASE; EPIGASTRIC DISCOMFORT; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GENETIC COUNSELING; GINGIVA HYPERPLASIA; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERHIDROSIS; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; LYMPHADENOPATHY; MYOTONIA; MYOTONIC DYSTROPHY; NAUSEA; NERVOUSNESS; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; OSTEOMALACIA; PANCREATITIS; PANCYTOPENIA; PATIENT MONITORING; PHOTOSENSITIVITY; PHYSIOTHERAPY; POLYURIA; PULSE RATE; RASH; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SYNCOPE; THOMSEN DISEASE; TREATMENT PLANNING; TREMOR; XEROSTOMIA;

EID: 77649275086     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-009-0055-z     Document Type: Review

References (51)

1. Preston DC, Shapiro BE: Electromyography and Neuromuscular Disorders, edn 2. Philadelphia: Elsevier Health Sciences; 2005.
2. F Lehmann-Horn K Jurkat-Rott R Rudel 2008 Diagnostics and therapy of muscle channelopathies-guidelines of the Ulm Muscle Center Acta Myologica 27 98 113 1:CAS:528:DC%2BD1MXmsVCjt7w%3D 19472919 The authors of this paper did a very good job of summarizing both the treatment and diagnosis of channelopathies involving muscle.
3. CR Heatwole R Moxley 3rd 2007 The nondystrophic myotonias Neurotherapeutics 4 2 238 251 10.1016/j.nurt.2007.01.012 1:CAS:528: DC%2BD2sXlt12rs7c%3D 17395134 This is another excellent review. It is especially good for diagnosis of the different myotonias. (Pubitemid 46467547)
4. C Lossin AL George Jr 2008 Myotonia congenita Adv Genet 63 25 55 10.1016/S0065-2660(08)01002-X 1:CAS:528:DC%2BD1MXht1ehsb%2FE 19185184 This is a very good review article, emphasizing the genetics of myotonia congenita.
5. O Bandschapp HF Ginz CL Soule, et al. 2009 In vitro effects of propofol and volatile agents on pharmacologically induced chloride channel myotonia Anesthesiology 111 584 590 10.1097/ALN.0b013e3181b05f23 1:CAS:528: DC%2BD1MXhtVekt7rP 19672179 Although this is an in vitro study, it shows that propofol may be a good anesthesia choice in patients with chloride channel myotonias. Further in vivo studies are warranted.
6. Harper PS: Myotonic Dystrophy, edn 3. London: WB Saunders; 2001.
7. B Udd G Meola R Krahe, et al. 2006 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management Neuromuscul Disord 16 6 403 413 10.1016/j.nmd.2006.03.010 1:STN:280:DC%2BD28zmvVShtw%3D%3D 16684600 (Pubitemid 43884790)
8. Katirji B, Kamininski H, Preston D, et al.: Neuromuscular Disorders in Clinical Practice. Boston: Butterworth-Heinemann; 2002.
9. H Kwiecinski B Ryniewicz A Ostrzycki 1992 Treatment of myotonia with antiarrhythmic drugs Acta Neurol Scand 86 4 371 375 10.1111/j.1600-0404.1992. tb05103.x 1:STN:280:DyaK3s%2FovV2rsQ%3D%3D 1455983
10. R Kratz RJ Hawley LK Jackson, et al. 1986 Treatment of myotonia with mexiletine Muscle Nerve 9 suppl 5 199
11. Meola G, Sansone V: Treatment in myotonia and periodic paralysis. Rev Neurol (Paris) 2004, 180(5 pt 2):4S55-4S69.
12. J Trip GG Drost B van Engelen CG Faber 2006 Drug treatment for myotonia Cochrane Database Syst Rev 1 CD004762 16437496
13. AS Monolis TF Dearing J Cameron, et al. 1990 Mexiletine: pharmacology and therapeutic uses Clin Cardiol 13 5 349 359 10.1002/clc.4960130509
14. RW Campbell 1987 Mexiletine N Engl J Med 316 29 34 1:STN:280: DyaL2s%2FmsV2ksA%3D%3D 3537793
15. AS Catalono A Corocci C Filomena, et al. 2008 Constrained analogs of tocainide as potent skeletal muscle sodium blockers towards the development of antimyotonic agents Eur J Med Chem 43 11 2535 2540 10.1016/j.ejmech.2008.01.023
16. R Rudel R Dengler K Ricker 1980 Improved therapy of myotonia with the lidocaine derivative tocainide J Neurol 244 4 275 278 10.1007/BF00313157
17. MR Savitha B Krishnamurthy A Hyderi, et al. 2006 Myotonia congenita-a successful response to carbamazepine Ind J Pediat 73 57 59
18. GP Sechi S Traccis L Durelli, et al. 1983 Carbamazepine versus diphenylhydantoin in the treatment of myotonia Eur Neurol 22 2 113 118 10.1159/000115546 1:STN:280:DyaL3s7ot1GktQ%3D%3D 6341070
19. R Aichele H Palik AH Heller 1985 Efficacy of phenytoin, procainamide, and tocainide in murine genetic myotonia Exp Neurol 87 2 377 381 10.1016/0014-4886(85)90228-6 1:CAS:528:DyaL2MXht1GisLo%3D 3917928 (Pubitemid 15174411)
20. JW Gerst RA Brumback RD Staton 1984 Lithium-induced improvement of myotonia J Neurol Neurosurg Psychiatry 47 9 1044 1046 10.1136/jnnp.47.9.1044-a 1:STN:280:DyaL2M%2FgvVOltA%3D%3D 6090591
21. EF Hughes J Wilson 1991 Response to treatment with antihistamines in a family with myotonia congenita Lancet 337 28 30 10.1016/0140-6736(91)93342-7 1:STN:280:DyaK3M%2FoslKjtg%3D%3D 1670657
22. MA Allford 2007 Prolonged myotonia and dystonia after general anaesthesia in a patient taking gabapentin Br J Anaesth 99 2 218 220 10.1093/bja/aem130 1:STN:280:DC%2BD2szpvVWqsw%3D%3D 17513320 (Pubitemid 47249393)
23. T Heiman-Patterson C Martino H Rosenburg, et al. 1988 Malignant hyperthermia in myotonia congenita. Neurology 38 810 812 1:STN:280: DyaL1c3gt1CnsQ%3D%3D
24. E Farbo E Softeland A Bindoff 2005 Anesthetic complications associated with myotonia congenita: a case study and comparison with other myotonic disorders Acta Anesthesiol Scand 47 630 634 10.1034/j.1399-6576.2003.00116.x
25. SH Russel NP Hirsch 1994 Anaesthesia and myotonia Br J Anaesth 72 210 216 10.1093/bja/72.2.210
26. M Sugino N Ohsawa T Ito, et al. 1998 A pilot study of dehydroepiandrosterone sulfate in myotonic dystrophy Neurology 51 586 589 1:CAS:528:DyaK1cXls1ags74%3D 9710041
27. I Pénisson-Besnier M Devillers R Porcher, et al. 2008 Dehydroepiandrosterone for myotonic dystrophy type 1 Neurology 71 407 412 10.1212/01.wnl.0000324257.35759.40 18678823
28. G Örndahl G Grimby A Grimby, et al. 1994 Functional deterioration and selenium-vitamin E treatment in myotonic dystrophy. A placebo-controlled study J Intern Med 235 3 205 210 10.1111/j.1365-2796.1994.tb01061.x 8120515
29. M Walter P Reilich H Lochmüller 2002 Creatine monohydrate in myotonic dystrophy: a double-blind, placebo-controlled clinical study J Neurol 249 1717 1722 10.1007/s00415-002-0923-x 1:CAS:528:DC%2BD3sXhsFygt7g%3D 12529796 (Pubitemid 36269266)
30. M Tarnopolsky D Mahoney T Thompson, et al. 2004 Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1 Muscle Nerve 29 51 58 10.1002/mus.10527 1:CAS:528:DC%2BD2cXhtVOhs7o%3D 14694498 (Pubitemid 38040556)
31. G Gascon RD Staton B Patterson, et al. 1989 A pilot controlled study of the use of imipramine to reduce myotonia Am J Phys Med Rehabil 68 5 215 220 10.1097/00002060-198910000-00003 1:STN:280:DyaK3c%2FislKisQ%3D%3D 2803681
32. G Antonini R Vichi MG Leardi 1990 Effect of clomipramine on myotonia: a placebo-controlled, double-blind, crossover trial Neurology 40 9 1473 1474 1:STN:280:DyaK3czmtlChuw%3D%3D 2202927
33. G Bassez A Lazarus I Desguerre 2004 Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1 Neurology 63 10 1939 1941 1:STN:280:DC%2BD2crosFOltA%3D%3D 15557517
34. A Fayssoil 2008 Should we perform systematic electrophysiological study in Steinert's disease? J Cardiothorac Surg 3 56 10.1186/1749-8090-3-56 18928563
35. J Mathieu P Allard L Potvin, et al. 1999 A 10-year study of mortality in a cohort of patients with myotonic dystrophy Neurology 52 1658 1:STN:280:DyaK1M3mtVGgug%3D%3D 10331695
36. A Lazarus J Varin Z Ounnoughene, et al. 1999 Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy Circulation 99 1041 1046 1:STN:280:DyaK1M7mtVGisg%3D%3D 10051298
37. WJ Groh MR Groh C Saha, et al. 2008 Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1 N Engl J Med 358 25 2688 2697 10.1056/NEJMoa062800 1:CAS:528:DC%2BD1cXns1ajsbw%3D 18565861 (Pubitemid 351860861)
38. Dello Russo A, Mangiola F, Della Bella P, et al.: Risk of arrhythmias in myotonic dystrophy: trial design of the RAMYD study. J Cardiovasc Med (Hagerstown) 2009, 10(1):51-58.
39. WJ Groh MR Lowe DP Zipes 2002 Severity of cardiac conduction involvement and arrhythmias in myotonic dystrophy type 1 correlates with age and CTG repeat length J Cardiovasc Electrophysiol 13 444 448 10.1046/j.1540-8167.2002.00444.x 12030525
40. J Nitz B Burke 2002 A study of the facilitation of respiration in myotonic dystrophy Physiother Res Int 7 4 228 238 10.1002/pri.262 12528578
41. JR MacDonald JD Hill MA Tarnopolsky 2002 Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy Neurology 59 1876 1880 1:STN:280:DC%2BD38jjsFKhtg%3D%3D 12499477
42. E Ciafaloni E Mignot V Sansone 2008 The hypocretin neurotransmission system in myotonic dystrophy type 1 Neurology 70 226 230 10.1212/01.wnl. 0000296827.20167.98 1:CAS:528:DC%2BD1cXitlOqtA%3D%3D 18195268
43. K Talbot J Stradling J Crosby, et al. 2003 Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy Neuromuscul Disord 13 357 364 10.1016/S0960-8966(03)00030-0 1:STN:280:DC%2BD3s3nt1yjsQ%3D%3D 12798791 (Pubitemid 36687811)
44. D Orlikowski S Chevret MA Quera-Salva, et al. 2009 Modafinil for the treatment of hypersomnia associated with myotonic muscular dystrophy in adults: a multicenter, prospective, randomized, double-blind, placebo-controlled, 4-week trial Clin Therapeut 31 8 1765 1773 10.1016/j.clinthera.2009.08.007 1:CAS:528:DC%2BD1MXht12gs7%2FF
45. AR Wintzen GJ Lammers JG van Dijk 2007 Does modafinil enhance activity of patients with myotonic dystrophy? A double-blind placebo-controlled crossover study J Neurol 254 26 28 10.1007/s00415-006-0186-z 1:CAS:528: DC%2BD2sXksVejtLk%3D 17285226 (Pubitemid 46295064)
46. G Meola V Sansone D Perani, et al. 2003 Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2) Neuromuscul Disord 13 10 813 821 10.1016/S0960-8966(03)00137-8 1:STN:280:DC%2BD3srpslGlsg%3D%3D 14678804 (Pubitemid 37532731)
47. J Mathieu P Allard G Gobeil, et al. 1997 Anesthetic and surgical complications in 219 cases of myotonic dystrophy Neurology 49 1646 1650 1:STN:280:DyaK1c%2FntlyhtA%3D%3D 9409361
48. MC Orngreen DB Olsen J Vissing 2005 Aerobic training in patients with myotonic dystrophy type 1 Ann Neurol 57 5 754 757 10.1002/ana.20460 15852373 (Pubitemid 40628867)
49. Sackley C, Disler PB, Turner-Stokes L, et al.: Rehabilitation interventions for foot drop in neuromuscular disease. Cochrane Database Syst Rev 2009, 3:CD003908.
50. TM Wheeler 2008 Myotonic dystrophy: therapeutic strategies for the future Neurotherapeutics 5 4 592 600 10.1016/j.nurt.2008.08.001 19019311
51. Aartsma-Rus A, van Ommen GJ: Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 2009 Oct 7 (Epub ahead of print).